History & Mission Statement
Oligomerix was founded in 2006 and has focused its research efforts on the role of tau protein in neurodegenerative disease. The Company has developed a biotechnology platform that has propelled its lead program from biochemical assays to in vivo studies and through de-risking pre-IND.
Oligomerix is an early-stage biotechnology company focused on discovering and developing novel, small molecule tau oligomer inhibitors for Alzheimer’s disease and related neurodegenerative diseases with tau pathology. The Company’s validated small molecule leads and companion biomarker assays will enable strategic partners to accelerate and de-risk clinical development in the pursuit of disease-modifying treatments.